New York, February 3, 2026, 14:46 (EST) — Regular session
- BSX dipped about 0.7% in afternoon trade, earlier fluctuating between $93.01 and $90.85.
- Michael F. Mahoney, an officer and director, filed a Form 144 signaling a possible sale of up to 160,901 shares
- Earnings call is set for Wednesday morning; the next major update won’t arrive until the late-March Watchman trial readout
Boston Scientific (BSX.N) dipped about 0.7% to $91.20 in afternoon action Tuesday, after swinging between $93.01 and $90.85. Roughly 10.4 million shares traded.
The medtech company is set to release its fourth-quarter results Wednesday, with a conference call scheduled for 8 a.m. ET, per its investor site. Investors will focus on the earnings report, along with guidance and procedure demand trends.
Josh Jennings at TD Cowen stuck with a Buy rating and kept his $115 price target steady, pointing to the late March CHAMPION-AF data for the Watchman implant as a key catalyst. He expects those results to be released at the American College of Cardiology meeting on March 28.
CHAMPION-AF is comparing left atrial appendage closure—a method that blocks a small heart pouch prone to clot formation—with newer oral anticoagulants in atrial fibrillation patients, the company announced. The study seeks to position the device as a first-line treatment, potentially broadening its application if it hits the trial’s targets.
Shares fell 1.8% Monday to close at $91.87, with about 15.4 million changing hands, per market data.
A filing with the U.S. Securities and Exchange Commission shows that Michael F. Mahoney, an officer and director, submitted a Form 144 notice to sell up to 160,901 shares through Morgan Stanley Smith Barney. These shares are valued at roughly $15.0 million. Keep in mind, filing a Form 144 signals an intent to sell under SEC Rule 144 but doesn’t confirm any shares have actually changed hands.
Abbott Laboratories slipped about 0.6% within the broader device sector. Medtronic, on the other hand, gained close to 1.0%. Edwards Lifesciences fell slightly, down roughly 0.4%.
Boston Scientific is zeroing in on how management frames 2026. Procedure demand, pricing, and margins tend to move the stock as much as the quarterly numbers themselves.
According to Kiplinger’s weekly earnings calendar, analysts expect earnings around 78 cents per share this quarter.
Expectations around earnings can shift fast. A cautious outlook or trial results that leave blood thinner use unchanged would likely weigh on sentiment.
The report drops Wednesday, followed by the 8 a.m. ET call. After that, attention shifts to the March 28 CHAMPION-AF update, the next major date traders are eyeing.
